SynBiotic SE (FRA:SBX)

Germany flag Germany · Delayed Price · Currency is EUR
2.595
-0.045 (-1.70%)
Last updated: Oct 21, 2025, 4:19 PM CET
-1.70%
Market Cap19.95M
Revenue (ttm)3.86M
Net Income (ttm)-10.63M
Shares Outn/a
EPS (ttm)-2.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,148
Average Volume832
Open2.685
Previous Close2.640
Day's Range2.590 - 2.685
52-Week Range2.580 - 6.720
Betan/a
RSI35.09
Earnings DateNov 14, 2025

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany. [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Employees 55
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol SBX
Full Company Profile

Financial Performance

In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.

Financial Statements

News

EQS-News: SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate

EQS-News: SYNBIOTIC SE / Key word(s): Statement SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate 21.10.2025...

1 day ago - Wallstreet:Online

Temporary headwinds from regulatory uncertainty; chg. est.

SYNBIOTIC faces short-term challenges due to regulatory uncertainties, prompting a reduction in FY25 guidance. Despite this, long-term growth potential remains, with a new BUY rating at € 6.00 PT. Jet...

2 days ago - Wallstreet:Online

EQS-News: Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals

EQS-News: SYNBIOTIC SE / Key word(s): Study/Miscellaneous Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals 02.10.2025 / 13:26 CET/CEST The issuer is sole...

19 days ago - Wallstreet:Online

EQS-News: Across the pond: SYNBIOTIC attracts international investors with established intercontinental networks

EQS-News: SYNBIOTIC SE / Key word(s): Alliance/Strategic Company Decision Across the pond: SYNBIOTIC attracts international investors with established intercontinental networks 14.08.2025 / 11:19 CET/...

2 months ago - Wallstreet:Online

SynBiotic Eyes Triple Revenue by 2027 in Cannabis & Hemp Markets

SYNBIOTIC SE is set to triple its revenue by 2027, leveraging growth in medical cannabis and industrial hemp markets, with a strategic focus on sustainable expansion and unique investment opportunitie...

3 months ago - Wallstreet:Online

EQS-DD: SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as part of a securities lending programme.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 23.04.2025 / 09:22 CET/CEST The issuer is solely responsi...

6 months ago - Wallstreet:Online